NTRA ▲ +0.2% - Natera, Inc. $NTRA - Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM Natera shares rose 0.2% following the company's announcement of results from the largest minimal residual disease study in lung cancer, which demonstrated strong prognostic value for its Signatera test. The positive data on a blood-based cancer detection tool may support the company's clinical positioning and market opportunity in oncology monitoring. 18-SEP-2026 06:09 AM ET